Mesenchymal stem cell-based product for acute graft-versus-host disease
TEMCELL® HS Inj.
TEMCELL® HS Inj. is the world’s first therapeutic product using
mesenchymal stem cells for the treatment of acute
graft-versus-host disease (acute GVHD), a severe complication
arising from hematopoietic stem cell transplant. The product
was approved in September 2015 as Japan’s first allogeneic
regenerative medical product and launched in February 2016.
TEMCELL® HS Inj.is a innovative product of isolated and expanded
mesenchymal stem cells (MSCs) derived from bone marrow aspirate of
a healthy adult donor. Being an off-the-shelf product, it is widely available for
patients in need, and we expect TEMCELL® HS Inj. to be a new treatment option
for patients with Acute GVHD.
Ultra-low temperature must be kept during transportation of TEMCELL® HS Inj.
in order to maintain its quality. We operate an ultra-low cold chain system jointly
developed with MEDIPAL HOLDINGS CORPORATION to ensure timely delivery
of high-quality products to clinical sites across Japan.
・Acute graft-versus-host disease following hematopoietic stem cell transplant